Exploring the Role of GLP-1 Receptor Agonists in Ocular Disorders: An In-Depth Analysis of Existing Studies and Future Directions - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Role of GLP-1 Receptor Agonists in Ocular Disorders: An In-Depth Analysis of Existing Studies and Future Directions

  • By

  • Yu Luo

  • Yanting Xia

  • Xiaohong Gong

  • Meiling Hao

  • Qiping Wei

  • Liang Liao

  • January 8, 2026

Share

  • 1

    GLP-1 receptor agonists (GLP-1RAs) enhance insulin secretion and are first-line treatments for type 2 diabetes and obesity management.

  • 2

    GLP-1RAs have potential therapeutic roles in ocular diseases, addressing unmet needs in conditions like diabetic retinopathy and glaucoma.

  • 3

    Current treatments for age-related macular degeneration (AMD) do not adequately address late-stage atrophic AMD, highlighting a critical therapeutic gap.

  • 4

    GLP-1RAs exhibit neuroprotective and anti-inflammatory properties, suggesting they may offer direct benefits for various eye diseases.

  • 5

    A comprehensive literature review identified studies on GLP-1RAs in ophthalmic disease, focusing on their effects on visual acuity and disease progression.

Original Source(s)

Related Content